The Filing Desk

Jazz Pharmaceuticals vs BeOne Medicines

Jazz Pharmaceuticals JAZZ · BeOne Medicines ONC · Pharmaceuticals

BeOne Medicines reported revenue of $5.3 billion in fiscal 2025, 1.3 times Jazz Pharmaceuticals' $4.3 billion in fiscal 2025. Jazz Pharmaceuticals' revenue grew 4.9% in its latest year, and BeOne Medicines' grew 40.2%. Jazz Pharmaceuticals had an operating margin of -10.1%, against 8.4% at BeOne Medicines. Free cash flow was $1.3 billion at Jazz Pharmaceuticals and $942 million at BeOne Medicines.

Side by side

Jazz PharmaceuticalsBeOne Medicines
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4.3B$5.3B
Revenue growth4.9%40.2%
Revenue growth a year, last 5 years12.5%76.8%
Gross margin—87.5%
Operating margin−10.1%8.4%
Net margin−8.3%5.4%
Free cash flow$1.3B$942M
Free cash flow margin30.4%17.6%
Return on capital−4.2%25.8%
Net debt to EBITDA—−6.3x
Dividends and buybacks$125M$0M
Change in diluted share count−7.6%7.8%
Last close$236.45$399.70
P/E at the last close77.0×—
Insider trades, last 12 monthssold $79.6 millionsold $361.1 million
Piotroski F-score4 of 88 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Jazz PharmaceuticalsBeOne Medicines
Operating margin
Percent of revenue
Jazz PharmaceuticalsBeOne Medicines
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Jazz PharmaceuticalsBeOne Medicines

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Jazz Pharmaceuticals and BeOne Medicines pages.